Clinical Trials & Results

Search or filter the listing below to find a trial or results of a completed trial.

View Actively Recruiting Clinical Trials

Click here to see trials currently recruiting participants

Filter

Health Condition

Toggle

Study Status

Toggle

Age group

Toggle

Gender

Toggle

Phase

Toggle

Study Types

Toggle

All Results

No results found

Please change the filter settings to find the product(s) you are looking for. You can also use the search function to look up a product.

Clear Filters

Long-Term Effect of TEV-48574 in Ulcerative Colitis or Crohn's Disease

cancer-icon.png
Condition(s):
Crohn's Disease, Colitis, Ulcerative
Status:
Active, not recruiting
Requirements:
Adult
Interventions:
Drug: TEV-48574
Learn more Primary objectives: The primary objective of the study is to evaluate the efficacy of 2 different maintenance dose regimens of TEV-48574 subcutaneous (sc) administered every 4 weeks (Q4W) in adult participants with inflammatory bowel disease (IBD). Secondary objective: Evaluate the efficacy of 2 different maintenance dose regimens of TEV-48574 sc administered Q4W in adult participants with IBD Evaluate the safety and tolerability of 2 different maintenance dose regimens of TEV-48574 sc administered Q4W in adult participants with IBDEvaluate the immunogenicity of 2 different maintenance dose regimens of TEV-48574 sc administered Q4W in adult participants with IBD The total duration for a participant in the double-blind period only is 66 weeks; and for a participant in the open-label extension (OLE) period, up to an additional 268 weeks.

Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents

headache-icon.png
Condition(s):
Migraine
Status:
Active, not recruiting
Requirements:
6 Years to 17 Years
Interventions:
Drug: Fremanezumab
Learn more Primary objectives: The primary objective of the study is to evaluate the long-term safety and tolerability of subcutaneous fremanezumab in the preventive treatment of migraine in pediatric participants 6 to 17 years of age (inclusive at enrollment in the pivotal study). Secondary objectives: Secondary objectives are to evaluate the efficacy of subcutaneous fremanezumab in pediatric participants with migraine and to evaluate the immunogenicity of fremanezumab and the impact of ADAs on clinical outcomes in pediatric participants exposed to fremanezumab. The total duration of the study is planned to be up to 60 months.